130 related articles for article (PubMed ID: 38212206)
21. Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study.
Wang PF; Yee CW; Gorsh B; Zichlin ML; Paka P; Bhak RH; Boytsov N; Khanal A; Noman A; DerSarkissian M; Ferrante S; Duh MS
Leuk Lymphoma; 2023 Feb; 64(2):398-406. PubMed ID: 36408998
[TBL] [Abstract][Full Text] [Related]
22. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma.
Abdallah AO; Sigle M; Mohyuddin GR; Coggins E; Remker C; Shune L; Mahmoudjafari Z; McGuirk J; Ganguly S
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e220-e226. PubMed ID: 33093009
[TBL] [Abstract][Full Text] [Related]
24. Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort.
Maouche N; Srinivasan A; Leary H; Collings F; Tseu B; Vallance GD; Ramasamy K; Kothari J
J Oncol Pharm Pract; 2023 Mar; 29(2):299-304. PubMed ID: 34939868
[TBL] [Abstract][Full Text] [Related]
25. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Siegel DS; Schiller GJ; Samaras C; Sebag M; Berdeja J; Ganguly S; Matous J; Song K; Seet CS; Talamo G; Acosta-Rivera M; Bar M; Quick D; Anz B; Fonseca G; Reece D; Pierceall WE; Chung W; Zafar F; Agarwal A; Bahlis NJ
Leukemia; 2020 Dec; 34(12):3286-3297. PubMed ID: 32376855
[TBL] [Abstract][Full Text] [Related]
26. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
[TBL] [Abstract][Full Text] [Related]
27. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
Le Ray E; Jagannath S; Palumbo A
Expert Rev Hematol; 2016 Jan; 9(1):91-105. PubMed ID: 26558304
[TBL] [Abstract][Full Text] [Related]
28. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial.
Bergin K; Yuen F; Wallington-Beddoe C; Kalff A; Sirdesai S; Reynolds J; Spencer A
Br J Haematol; 2021 Aug; 194(3):580-586. PubMed ID: 33991421
[TBL] [Abstract][Full Text] [Related]
30. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
[TBL] [Abstract][Full Text] [Related]
31. Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ
N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166
[TBL] [Abstract][Full Text] [Related]
32. Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study.
Ocio EM; Montes-Gaisán C; Bustamante G; Garzón S; González E; Pérez E; Sirvent M; Arguiñano JM; González Y; Ríos R; de Miguel D; Grande M; Fernández A; Naves A; Rosiñol L
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):e241-e249. PubMed ID: 34774462
[TBL] [Abstract][Full Text] [Related]
33. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
Piggin A; Prince HM
Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
[TBL] [Abstract][Full Text] [Related]
34. Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP).
Alegre A; Benzo G; Alonso R; Martínez-López J; Jimenez-Ubieto A; Cuéllar C; Askari E; Prieto E; Aláez C; Aguado B; Velasco A; Krsnik I; Bocanegra A; Llorente L; Muñoz-Linares C; Morales A; Giménez E; Iglesias R; Martínez-Chamorro C; Alonso A; Jiménez-Montes C; Blanchard MJ;
Oncol Ther; 2023 Mar; 11(1):83-96. PubMed ID: 36509945
[TBL] [Abstract][Full Text] [Related]
35. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
[TBL] [Abstract][Full Text] [Related]
36. Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
Visram A; De La Torre A; White D; Su J; Masih-Khan E; Chu M; Jimenez-Zepeda V; McCurdy A; LeBlanc R; Song K; Mian H; Louzada M; Sebag M; Bergstrom D; Stakiw J; Reiman A; Kotb R; Aslam M; Venner C; Kaedbey R; Gul E; Reece D
Blood Cancer J; 2023 Dec; 13(1):181. PubMed ID: 38065967
[TBL] [Abstract][Full Text] [Related]
37. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.
Kumar SK; Dimopoulos MA; Kastritis E; Terpos E; Nahi H; Goldschmidt H; Hillengass J; Leleu X; Beksac M; Alsina M; Oriol A; Cavo M; Ocio EM; Mateos MV; O'Donnell EK; Vij R; Lokhorst HM; van de Donk NWCJ; Min C; Mark T; Turesson I; Hansson M; Ludwig H; Jagannath S; Delforge M; Kyriakou C; Hari P; Mellqvist U; Usmani SZ; Dytfeld D; Badros AZ; Moreau P; Kim K; Otero PR; Lee JH; Shustik C; Waller D; Chng WJ; Ozaki S; Lee JJ; de la Rubia J; Eom HS; Rosinol L; Lahuerta JJ; Sureda A; Kim JS; Durie BGM
Leukemia; 2017 Nov; 31(11):2443-2448. PubMed ID: 28620163
[TBL] [Abstract][Full Text] [Related]
38. A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
Berdeja JG; Gregory TK; Faber EA; Hart LL; Mace JR; Arrowsmith ER; Flinn IW; Matous JV
Am J Hematol; 2021 Apr; 96(4):428-435. PubMed ID: 33421178
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).
Jing H; Yang L; Qi J; Qiu L; Fu C; Li J; Yang M; Qi M; Fan N; Ji J; Lu J; Li Y; Jin J
Ann Hematol; 2022 Dec; 101(12):2679-2690. PubMed ID: 36301338
[TBL] [Abstract][Full Text] [Related]
40. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
Du J; Fang B; Li J; Jin J; Wang S; Zou D; Cai Z; Wang H; Hu J; Li W; Fu C; Shao Z; Xia Z; Liu P; Niu T; Tang ET; Kimball AS; Hou J; Chen W
Int J Hematol; 2021 Mar; 113(3):422-429. PubMed ID: 33389656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
